Conjugation Product Comprising an Antigen Binding Moiety and a Mucin Binding Moiety

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a new type of conjugated biopharmaceutical in which an antigen binding moiety (such as an antibody that binds to viruses, bacteria, allergens, or sperm cells) is covalently linked to a mucin binding moiety. The mucin binding part enables the conjugate to adhere to mucus in the body (such as in the nose, respiratory tract, or reproductive system). This adjacency to mucus increases the binding efficacy of the antigen-binding portion, leading to better protection or therapeutic effects, for example in trapping pathogens or allergens at mucosal surfaces.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment and prevention of respiratory infections (e.g., SARS-CoV-2, influenza, RSV) via nasal or inhalation sprays that trap pathogens in airway mucus.
• Therapeutic interventions for bacterial infections in mucosal tissues like the respiratory or urogenital tract.
• Allergy mitigation by binding and clearing allergens in mucus of nasal or buccal tissues.
• Development of contraceptive formulations by binding and removing sperm cells in vaginal mucus, preventing fertilization.
• Enhanced mucosal vaccines that stay longer at the target site, leading to stronger immune responses in mucosal tissues.
• Use as combination therapy with standard antiviral or antibacterial treatments to enhance pathogen clearance at mucosal surfaces.

BenefitsContent extracted from patent full text and abstract with AI.

• Increased efficacy of existing and future biotherapeutics due to improved retention and activity at mucosal surfaces.
• Reduced dosage and improved duration of action, since the conjugate stays localized in mucus for longer periods.
• Broad applicability: can be adapted for various targets, including viruses, bacteria, allergens, and sperm cells.
• Minimized systemic exposure and side effects, as the action is localized to mucosal tissue rather than the whole body.
• Potential for rapid deployment in sprays or gels for prophylactic or therapeutic use (e.g., nasal sprays in a pandemic context).
• Allows for tunable efficacy by changing the ratio or type of mucin binding and antigen binding moieties.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a conjugation product comprising an antigen binding moiety and a mucin binding moiety covalently bound to the antigen binding moiety. Due to the mucin binding moiety, the antigen binding efficacy of the antigen binding moiety is significantly increased.